ArticleCell reports. Medicine2026

Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series.

Tobias Hegelmaier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.